ClinicalTrials.gg
CompletedNCT01824342Updated Mar 5, 2015Results posted

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

A Phase 3 interventional study of Denosumab in Castrate-resistant Prostate Cancer, sponsored by Amgen. Completed at 9 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-05.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing denosumab in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Denosumab · Prostatic Neoplasms.

Enrollment
9th of 10
18 · median 324
Started
2011
with 1 other
Phase 3
8 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
7 of 10
Amgen

Among the 10 studies testing denosumab in Prostatic Neoplasms, this one is the 9th largest by enrollment, is one of 2 that started in 2011, is one of 8 in phase 3, and was the 7th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 10 studies testing denosumab in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing denosumab in Prostatic Neoplasms as a file.
02

Study summary

This is a multi-national, multi-center, open-label, single-arm extension study for the prolongation of bone metastasis-free survival in men with hormone-refractory (androgen independent) prostate cancer. Patients currently participating in the phase 3 study 20050147 (NCT00286091) will be offered this study if a positive benefit:risk compared with placebo is determined in the 20050147 study. The primary endpoint of the 20050147 study is bone metastases-free survival determined by the time to first occurrence of bone metastases (either symptomatic or asymptomatic) or death from any cause. Participants will receive open-label denosumab administered once every 4 weeks (Q4W) subcutaneously (SC) until they developed a bone metastasis or for up to 3 years, whichever comes first.

03

Conditions studied

  • Castrate-resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects currently undergoing every 4 weeks scheduled assessments in the phase 3 study 20050147
  • Subjects must sign the before any study specific procedures are performed

Exclusion criteria

Exclusion Criteria:

  • Developed sensitivity to mammalian cell derived drug products during the 20050147 study
  • Currently receiving any unapproved product other than denosumab
  • Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written and/or comply with study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Denosumab

    Participants received denosumab 120 mg subcutaneously every 4 weeks for up to 3 years in this open-label extension study.

    Biological: Denosumab

Interventions

  • BiologicalDenosumab

    Administered by subcutaneous injection

    Also known as: XGEVA®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (AEs) and Deaths

    A serious adverse event is defined as an adverse event that meets at least one of the following serious criteria: • fatal, • life threatening, • requires in-patient hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, • congenital anomaly/birth defect, and/or • other significant medical hazard. The adverse event severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, according to the following: Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. The investigator assessed whether each adverse event was possibly related to the investigational product (IP).

    Time frame: From the first dose of open-label denosumab until 4 weeks after the last; maximum time on study was 37 months. Follow-up survival information was collected for up to 3 years after the last dose of blinded investigation product in the 20050147 study.

  2. Percent Change From Baseline in Laboratory Values

    Time frame: Baseline and Week 49

  3. Number of Participants With Anti-denosumab Neutralizing Antibody Formation

    Time frame: 3 years

Secondary outcomes

  1. Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)

    A scale used to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work); 2 = Ambulatory and capable of all self care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair; 5 = Dead.

    Time frame: Baseline and Week 49

07

Results

Posted Mar 5, 2015

Participant flow

This was a single-arm, open-label extension (OLE) phase of a phase 3, randomized, double-blind study (Study 20050147; NCT00286091) comparing denosumab with placebo on prolonging bone metastasis-free survival in men with hormone-refractory (androgen independent) prostate cancer.

Participant flow — Overall Study
MilestonePlacebo/DenosumabDenosumab/Denosumab
Started117
Completed22
Not completed95
Withdrew: Withdrawal by subject03
Withdrew: Adverse event11
Withdrew: Disease progression11
Withdrew: Physician decision50
Withdrew: Death20

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (AEs) and Deaths

A serious adverse event is defined as an adverse event that meets at least one of the following serious criteria: • fatal, • life threatening, • requires in-patient hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, • congenital anomaly/birth defect, and/or • other significant medical hazard. The adverse event severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, according to the following: Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. The investigator assessed whether each adverse event was possibly related to the investigational product (IP).

Time frame:
From the first dose of open-label denosumab until 4 weeks after the last; maximum time on study was 37 months. Follow-up survival information was collected for up to 3 years after the last dose of blinded investigation product in the 20050147 study.
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (AEs) and Deaths
participantsPlacebo/DenosumabDenosumab/Denosumab
Any adverse event (AE)117
Serious adverse event74
Fatal adverse event20
AE leading to study discontinuation21
AE leading to IP discontinuation41
CTCAE Grade 3, 4, or 562
AE related to investigational product (IP)23
Serious AE related to IP02
Fatal AE related to IP00
AE related to IP leading to study discontinuation11
AE related to IP leading to IP discontinuation11
AE related to IP and CTCAE Grade 3, 4, or 501
Deaths41
Deaths on study20
Deaths during the safety follow-up21
PrimaryPercent Change From Baseline in Laboratory Values
Time frame:
Baseline and Week 49
Reported as:
Mean · percent change
Percent Change From Baseline in Laboratory Values
percent changePlacebo/DenosumabDenosumab/Denosumab
Albumin-adjusted Calcium-0.9 ± 2.51.1 ± 3.1
Alkaline Phosphatase-23.8 ± 21.8-1.6 ± 20.5
Creatinine16.3 ± 31.52.4 ± 5.8
Phosphorus-2.6 ± 25.20.0 ± 10.4
PrimaryNumber of Participants With Anti-denosumab Neutralizing Antibody Formation
Time frame:
3 years
Reported as:
Number · participants
Number of Participants With Anti-denosumab Neutralizing Antibody Formation
participantsPlacebo/DenosumabDenosumab/Denosumab
Number of Participants With Anti-denosumab Neutralizing Antibody Formation00
SecondaryChange From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)

A scale used to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work); 2 = Ambulatory and capable of all self care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair; 5 = Dead.

Time frame:
Baseline and Week 49
Reported as:
Number · participants
Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
participantsPlacebo/DenosumabDenosumab/Denosumab
4-point increase in PS00
3-point increase in PS00
2-point increase in PS00
1-point increase in PS01
No change105
1-point decrease in PS00
2-point decrease in PS00

Adverse events

Collected over 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/ Denosumab 120 mg Q4W—7/11 (63.6%)11/11 (100%)
Denosumab/ Denosumab 120 mg Q4W—4/7 (57.1%)6/7 (85.7%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPlacebo/ Denosumab 120 mg Q4WDenosumab/ Denosumab 120 mg Q4W
Osteonecrosis of jawMusculoskeletal and connective tissue disorders0/112/7
Urinary tract infectionInfections and infestations2/110/7
Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/110/7
HydronephrosisRenal and urinary disorders2/110/7
Urinary retentionRenal and urinary disorders2/110/7
PhimosisCongenital, familial and genetic disorders0/111/7
DyspnoeaRespiratory, thoracic and mediastinal disorders0/111/7
HaemoptysisRespiratory, thoracic and mediastinal disorders0/111/7
Mitral valve incompetenceCardiac disorders1/110/7
Myocardial infarctionCardiac disorders1/110/7
Most frequent other events
Showing 10 of 120
Most frequent other events
EventPlacebo/ Denosumab 120 mg Q4WDenosumab/ Denosumab 120 mg Q4W
Back painMusculoskeletal and connective tissue disorders4/110/7
Urinary tract infectionInfections and infestations3/112/7
Prostatic specific antigen increasedInvestigations2/112/7
AnaemiaBlood and lymphatic system disorders3/110/7
FatigueGeneral disorders3/110/7
Oedema peripheralGeneral disorders3/111/7
DizzinessNervous system disorders3/110/7
HaematuriaRenal and urinary disorders3/111/7
DiarrhoeaGastrointestinal disorders2/110/7
VomitingGastrointestinal disorders2/111/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo/DenosumabDenosumab/DenosumabTotal
Mean71.6 ± 4.370.3 ± 7.471.1 ± 5.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/DenosumabDenosumab/DenosumabTotal
Female000
Male11718
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo/DenosumabDenosumab/DenosumabTotal
White or Caucasian11718
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Placebo/DenosumabDenosumab/DenosumabTotal
Grade 07512
Grade 1415
Grade 2011
Grade 3000
Grade 4000
Albumin-adjusted calcium
Albumin-adjusted calcium(mmol/L)Placebo/DenosumabDenosumab/DenosumabTotal
Mean2.44 ± 0.102.42 ± 0.042.43 ± 0.08
Creatinine
Creatinine(umol/L)Placebo/DenosumabDenosumab/DenosumabTotal
Mean88.40 ± 14.2589.66 ± 23.6388.89 ± 17.80
Phosphorus
Phosphorus(mmol/L)Placebo/DenosumabDenosumab/DenosumabTotal
Mean1.09 ± 0.221.01 ± 0.241.06 ± 0.22
08

Study locations

9 sites
  • Research Site
    Hradec Kralove, 500 05, Czech Republic
  • Research Site
    Pelhrimov, 393 38, Czech Republic
  • Research Site
    Praha 2, 128 08, Czech Republic
  • Research Site
    Praha 6, 160 00, Czech Republic
  • Research Site
    Tabor, 390 03, Czech Republic
  • Research Site
    Newcastle, NE7 7DN, United Kingdom
  • Research Site
    Northwood, HA6 2RN, United Kingdom
  • Research Site
    Sheffield, S10 2SJ, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2013
First posted
Apr 4, 2013
Start
Jan 2011
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Mar 5, 2015
Last update
Mar 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01824342
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 4, 2013
Start date
Jan 2011
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Mar 5, 2015
Last update
Mar 5, 2015

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion